The relationship between myeloid-derived supressor cells and clinico-laboratory parameters in patients with liver cyrrosis

Abstract

In the present study, we used multicolor flow cytometry assay to measure the numbers of various myeloid suppressor cell subpopulations (Lin-HLA-DR-CD33+, Lin-HLA-DR-CD33+CD66b+, and CD14+HLA-DRlow/-) in peripheral blood of 51 participants, including 33 patients with viral- and 1 8 patients with «nonviral» (alcoholic or biliary/autoimmune) liver cirrhosis. Patients in both groups had increased proportions of Lin-HLA-DR-CD33+, Lin-HLA-DR-CD33+CD66b+, and CD 14+HLA-DRlow/-cells which levels did not depend on the type and replication of the virus in viral liver cirrhosis. In viral liver cirrhosis, the relative numbers of Lin-HLA-DR-CD33+cells directly correlated with the albumin levels (Rs=0.45; p=0.029). In «nonviral» group an inverse relationship was found between these indicators (Rs = -0.56; p=0.02), in addition the proportion of Lin-HLA-DR-CD33+and CD14+HLA-DRlow/-cells directly correlated with disease severity scores (Child-Pugh and MELD) direct correlation of the proportion of Lin-HLA-DR-CD33+and CD14+HLA-DRlow/-cells with the disease severity scores (Child-Pugh and MELD). Comparison of the initial content of myeloid suppressors with the response to complex therapy (that included autologous bone marrow-derived cell transplantation), showed that in viral liver cirrhosis, the proportion of Lin-HLA-DR-CD33+cells was characterized by a prognostic significance and, at values <1.9%, allowed to predict a decrease in the Child-Pugh score at 12 month follow-up with a sensitivity of 83.3% and a specificity of 71.4%. The data obtained indicate the relationship between myeloid-derived suppressor cells and albumin levels, disease severity and response to therapy, suggesting myeloid suppressors as a new therapeutic target in the liver cirrhosis.

Keywords

myeloid-derived suppressor cells / liver cirrhosis / disease severity / prognosis / ROC-analysis

References

[1] Albillos A., Martin-Mateos R., Van der Merwe S. et al. Cirrhosis-associated immure dysfunction. Nat. Rev. Gastroenterol. Hepatol. 2021; 61(6): 1385-96.

[2] Gabrilovich D.I. Myeloid-derived suppressor cells. Cancer Immunol. Res. 2017; 5(1): 3-8.

[3] Rajabinejad M., Salari F., Karaji A.G. et al. The role of myeloid-derived suppressor cells in the pathogenesis of rheumatoid arthritis; anti- or pro-inflammatory cells? Artif. Cells, Nanomed. Biotechnol. 2019; 47(1): 4149-58.

[4] Consonni F.M., Porta C., Marino A. et al. Myeloid-Derived Suppressor Cells: Ductile Targets in Disease. Front. Immunol. 2019; 10: 949.

[5] Veglia F., Sanseviero E., Gabrilovich D.I. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat. Rev. Immunol. 2021; 21: 485-98.

[6] Sehgal R., Kaur N., Ramakrishna G. et al. Immune surveillance by Myeloid derived suppressor cells (MDSCs) in liver diseases. Dig. Dis. 2021; doi: 10.1159/000517459.

[7] Hammerich L., Tacke F. Emerging roles of myeloid derived suppressor cells in hepatic inflammation and fibrosis. World J. Gastrointest. Pathophysiol. 2015; 6(3): 43-50.

[8] Zhou G.P., Jiang Y.Z., Sun L.Y. et al. Therapeutic effect and safety of stem cell therapy for chronic liver disease: a systematic review and metaanalysis of randomized controlled trials. Stem Cell Res. Ther. 2020; 11: 419.

[9] Shevela E.Y., Starostina N., Pal'tsev A. et al. Efficiency of Cell Therapy in Liver Cirrhosis. Bull. Exp. Biol. Med. 2016; 160(4): 542-7.

[10] Bernsmeier C., Triantafyllou E., Brenig R. et al. CD14+ CD15-HLA-DR- myeloid-derived suppressor cells impair antimicrobial responses in patients with acute-on-chronic liver failure. Gut 2018; 67(6): 1155-67.

[11] Li H., Dai F., Peng Q. et al. Myeloid-derived suppressor cells suppress CD4+ and CD8+ T cell responses in autoimmune hepatitis. Mol. Med. Rep. 2015; 12(3): 3667-73.

[12] Longhi M.S., Ma Y., Vergani М. et al. Aetiopathogenesis of autoimmune hepatitis. J. Autoimmun. 2010; 34: 7-14.

[13] Kong X., Sun R., Chen Y. et al. yST cells drive myeloid-derived suppressor cell mediated CD8+ T cell exhaustion in hepatitis B virus-induced immunotolerance. J. Immunol. 2014; 193(4): 1645-53.

[14] Zhang H., Lian M., Zhang J. et al. A functional characteristic of cysteine-rich protein 61: modulation of myeloid-derived suppressor cells in liver inflammation. Hepatology 2018; 67(1): 232-46.

[15] Zeng Q., Yang B., Sun H.Q. et al. Myeloid-derived suppressor cells are associated with viral persistence and downregulation of TCR Z chain expression on CD8 (+) T cells in chronic hepatitis C patients. Mol. Cells 2014; 37(1): 66.

[16] Suh Y.G., Kim J., Byun J. et al. CD11b(+) Gr1(+) bone marrow cells ameliorate liver fibrosis by producing interleukin-10 in mice. Hepatology 2012; 56(5): 1902-12.

RIGHTS & PERMISSIONS

Eco-Vector